Calamos Advisors
MYOV

Calamos Advisors’s Myovant Sciences Ltd. MYOV Stock Holding History

Calamos Advisors’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-125,649
Closed -$3.47M – 983
2020
Q4 		$3.47M Buy
125,649
+23,115
+23% +$450K 0.02% 557
2020
Q3 		$1.44M Buy
+102,534
New +$1.91M 0.01% 617

Other funds holding MYOV

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

Calamos Advisors's MYOV Position: Q1 2021 in Review

Calamos Advisors sold out of Myovant Sciences Ltd. (MYOV) in Q1 2021, closing a stake of 125,649 shares — an estimated $3.47M sold.

Calamos Advisors first reported a position in MYOV in Q3 2020 and held it in 2 quarters. The position peaked at $3.47M in Q4 2020. 104 funds tracked by Wall St. Rank hold MYOV as of Q1 2021.

  • Calamos Advisors reported no remaining Myovant Sciences Ltd. position as of Q1 2021 after selling out during the quarter.
  • Calamos Advisors sold 125,649 Myovant Sciences Ltd. shares in Q1 2021, an estimated $3.47M.
  • Calamos Advisors first reported a position in Myovant Sciences Ltd. in Q3 2020 and held it in 2 quarters.
  • Calamos Advisors's Myovant Sciences Ltd. position peaked at $3.47M in Q4 2020.
  • 104 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2021.

Based on Calamos Advisors's 13F filing for Q1 2021, filed 12 Apr 2021.